These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 17356986)

  • 1. Estimating the impact of adding C-reactive protein as a criterion for lipid lowering treatment in the United States.
    Woloshin S; Schwartz LM; Kerin K; Welch HG
    J Gen Intern Med; 2007 Feb; 22(2):197-204. PubMed ID: 17356986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of reclassifying moderate CKD as a coronary heart disease risk equivalent on the number of US adults recommended lipid-lowering treatment.
    Hyre AD; Fox CS; Astor BC; Cohen AJ; Muntner P
    Am J Kidney Dis; 2007 Jan; 49(1):37-45. PubMed ID: 17185144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: data from National Health and Nutrition Examination Survey 1999 to 2002.
    Keevil JG; Cullen MW; Gangnon R; McBride PE; Stein JH
    Circulation; 2007 Mar; 115(11):1363-70. PubMed ID: 17353444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale for targeted rather than population based screening with C-reactive protein using the National Health and Nutrition Examination Survey (1999 to 2002).
    Guttormsen BN; Stein JH; McBride PE; Cullen MW; Gangnon R; Keevil JG
    Am J Cardiol; 2007 Oct; 100(7):1130-3. PubMed ID: 17884376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate- and low-cardiovascular-risk individuals for statin therapy.
    Lee KK; Cipriano LE; Owens DK; Go AS; Hlatky MA
    Circulation; 2010 Oct; 122(15):1478-87. PubMed ID: 20876434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of different blood lipid evaluation and treatment guidelines on the proportion of Canadians identified and treated for elevated blood cholesterol. Canadian Heart Health Surveys Research Group.
    MacLean DR; Petrasovits A; Connelly PW; Little JA; O'Connor B
    Can J Cardiol; 1999 Apr; 15(4):445-51. PubMed ID: 10322254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contemporary management of dyslipidemia in high-risk patients: targets still not met.
    Yan AT; Yan RT; Tan M; Hackam DG; Leblanc KL; Kertland H; Tsang JL; Jaffer S; Kates ML; Leiter LA; Fitchett DH; Langer A; Goodman SG;
    Am J Med; 2006 Aug; 119(8):676-83. PubMed ID: 16887414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium.
    Goff DC; Bertoni AG; Kramer H; Bonds D; Blumenthal RS; Tsai MY; Psaty BM
    Circulation; 2006 Feb; 113(5):647-56. PubMed ID: 16461837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey.
    Spatz ES; Canavan ME; Desai MM
    Circ Cardiovasc Qual Outcomes; 2009 Jan; 2(1):41-8. PubMed ID: 20031811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on lipid-lowering therapy and LDL-cholesterol targets.
    Wiviott SD; Cannon CP
    Nat Clin Pract Cardiovasc Med; 2006 Aug; 3(8):424-36. PubMed ID: 16874355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implications of changing national cholesterol education program goals for the treatment and control of hypercholesterolemia.
    Persell SD; Lloyd-Jones DM; Baker DW
    J Gen Intern Med; 2006 Feb; 21(2):171-6. PubMed ID: 16390501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
    Sorensen SV; Frick KD; Wade A; Simko R; Burge R
    Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypercholesterolemia. The NCEP Adult Treatment Panel III Guidelines.
    Morgan JM; Capuzzi DM
    Geriatrics; 2003 Aug; 58(8):33-8; quiz 41. PubMed ID: 12938250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is measuring C-reactive protein useful for guiding treatment in women > or = 60 years and men > or = 50 years of age?
    Muntner P; Mann D; Razzouk L; Klarenbach S; Manns B; Tonelli M; Farkouh ME
    Am J Cardiol; 2009 Aug; 104(3):354-8. PubMed ID: 19616667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Waist circumference adds to the variance in plasma C-reactive protein levels in elderly patients with metabolic syndrome.
    Dupuy AM; Jaussent I; Lacroux A; Durant R; Cristol JP; Delcourt C
    Gerontology; 2007; 53(6):329-39. PubMed ID: 17551260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with discharge lipid-lowering drug prescription in patients hospitalized for coronary artery disease (from the Get With the Guidelines database).
    Albert NM; Birtcher KK; Cannon CP; Goff DC; Mulgund J; Liang L; Fonarow GC
    Am J Cardiol; 2008 May; 101(9):1242-6. PubMed ID: 18435951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of prevention on reducing the burden of cardiovascular disease.
    Kahn R; Robertson RM; Smith R; Eddy D
    Circulation; 2008 Jul; 118(5):576-85. PubMed ID: 18606915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensity of lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment among the elderly before and after the 2004 National Cholesterol Education Program Adult Treatment Panel III update.
    Nichols GA; Nag S; Chan W
    Am Heart J; 2007 Sep; 154(3):554-60. PubMed ID: 17719305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of high blood cholesterol levels in Nova Scotian adults: comparison with the NCEP II and European clinical practice guidelines.
    Kephart G; Sketris I; MacLean D; Kass K; Nagpal S
    Am J Manag Care; 2000 Sep; 6(9):1017-28. PubMed ID: 11184063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.